Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment

Arlette Bruijstens*, Katelijn Blok, Jill Smolders, Beatrijs Wokke, Rinze Neuteboom

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)
Original languageEnglish
Pages (from-to)1962-1964
Number of pages3
JournalMultiple Sclerosis Journal
Issue number14
Publication statusPublished - Dec 2020

Bibliographical note

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the
Dutch MS research Foundation.

Cite this